Labrador, Mark Eleazar B.
HRN: 02-03-25 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/08/2025
CEFTRIAXONE 1G (VIAL)
02/08/2025
02/15/2025
IV
2g
OD
Acute Uncomplicated Pyelonephritis; CAP-LR
Waiting Final Action
Indication: Empiric Type of Infection: Urinary TractPneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes